Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer

Journal of Clinical Oncology

Volumn 20, Issue 20, 2002, Pages 4225-4231

  Brett, B T ^a   Smith, S C ^a   Bouvier, C V ^a   Michaeli, D ^a   Hochhauser, D ^a   Davidson, B R ^a   Kurzawinski, T R ^a   Watkinson, A F ^a   Van Someren, N ^a   Pounder, R E ^a   Caplin, M E ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; G17DT; GASTRIN; GASTRIN 17; GASTRIN 17 ANTIBODY; GROWTH FACTOR; UNCLASSIFIED DRUG;

ABSCESS; ADULT; ADVANCED CANCER; ANTIBODY RESPONSE; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DIPHTHERIA TOXOID; FEMALE; GASTRINS; HUMANS; IMMUNIZATION; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 0037108933     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.151     Document Type: Article

References (30)

1. Bramhall SR, Allum WH, Jones AG, et al: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study. Br J Surg 82:111-115, 1995
2. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
3. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353, 1996
4. Burris H, Stornjolo AM: Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil. Eur J Cancer 33:S18-S22, 1997 (suppl 1)
5. Burris HA III: Objective outcome measures of quality of life. Oncology 10:131-135, 1996 (suppl 11)
6. Gebbia V, Majello E, Testa A, et al: Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule: Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Cancer 78:1300-1307, 1996
7. Cullinan S, Moertel CG, Wieand HS, et al: A phase III trial on the therapy of advanced pancreatic carcinoma: Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65:2207-2212, 1990
8. Brett BT, Caplin ME: Towards immunotherapy for pancreatic cancer. Gut 46:582-583, 2000 (letter)
9. McKenzie IF, Aposolopoulos V: Towards immunotherapy of pancreatic cancer. Gut 44:767-769, 1999
10. Bramhall SR: Novel non-operative treatment and treatment strategies in pancreatic cancer. Expert Opin Investig Drugs 9:1179-1195, 2000
11. Kroep JR, Pinedo HM, van Groeningen CJ, et al: Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 10:234-238, 1999 (suppl 4)
12. Rosemurgy A, Harris J, Langleben A, et al: Marimastat in patients with advanced pancreatic cancer: A dose-finding study. Am J Clin Oncol 22:247-252, 1999
13. Rosemurgy A, Harris J, Langleben A, et al: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 15:207, 1996 (abstr 470)
14. Watson SA, Michaeli D, Grimes S, et al: Gastrimmune raises antibodies that neutralise amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res 56:880-885, 1996
15. Smith JP, Fantaskey AP, Liu G, et al: Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 268(1 Pt 2):R135-R141, 1995
16. Smith JP, Shih A, Wu Y, et al: Gastrin regulates the growth of human pancreatic cancer in a tonic and autocrine fashion. Am J Physiol 270(5 Pt 2):R1078-R1084, 1996
17. Thorburn CM, Friedman GD, Dickinson CJ, et al: Gastrin and colorectal cancer. Gastroenterology 115:275-280, 1998
18. Brett BT, Caplin ME: Gastrin: Old hormone new possibilities. J Gastroenterol Hepatol Nutr 2:44-46, 1999
19. Wang TC, Koh TJ, Varro A, et al: Processing and proliferative effects of human progastrin in transgenic mice. J. Clin Invest 98:1918-1929, 1996
20. Seva C, Dickinson CJ, Yamada T: Growth-promoting effects of glycine-extended progastrin. Science 265:410-412, 1994
21. Negre F, Fagot-Revurat P, Bouisson M, et al: Autocrine stimulation of AR4-2J rat pancreatic tumor cell growth by glycine-extended gastrin. Int J Cancer 66:653-658, 1996
22. Majumdar AP, Nielsen H: Influence of glucocorticoids on prenatal development of the gut and pancreas in rats. Scand J Gastroenterol 20:65-71; 1985
23. Smith JP, Hamory MW, Verderame MF, et al: Quantitative analysis of gastrin mRNA and peptide in normal and cancerous human pancreas. Int J Mol Med 2:309-315, 1998
24. Caplin M, Savage K, Khan K, et al: Expression and processing of gastrin in pancreatic adenocarcinoma. Br J Surg 87:1035-1040, 2000
25. Goetze JP, Nielsen FC, Burcharth F, et al: Closing the gastrin loop in pancreatic carcinoma: Coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 88:2487-2494, 2000
26. Brett BT, Khan K, Savage K, et al: The effect of antibodies raised against Gastrimmune on the proliferation of human pancreatic carcinoma cell lines. Gut 44:W190, 1999 (suppl 1)
27. Smith AM, Justin T, Michaeli D, et al: Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin Cancer Res 6:4719-4724, 2000
28. Fishman B, Pasternak S, Wallenstein SL, et al: The Memorial Pain Assessment Card: A valid instrument for the evaluation of cancer pain. Cancer 60:1151-1158, 1987
29. Furuse M, Ao R, Bungo T, et al: Central gastrin inhibits feeding behaviour and food passage in neonatal chicks. Life Sci 65:305-311, 1999
30. Watson SA, Michael D, Justin TA, et al: Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model. Int J Cancer 75:873-877, 1998